651 related articles for article (PubMed ID: 29237099)
1. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
Rirash F; Tingey PC; Harding SE; Maxwell LJ; Tanjong Ghogomu E; Wells GA; Tugwell P; Pope J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD000467. PubMed ID: 29237099
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.
Maltez N; Maxwell LJ; Rirash F; Tanjong Ghogomu E; Harding SE; Tingey PC; Wells GA; Tugwell P; Pope J
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD014089. PubMed ID: 37929840
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
[TBL] [Abstract][Full Text] [Related]
4. Vasodilators for primary Raynaud's phenomenon.
Su KY; Sharma M; Kim HJ; Kaganov E; Hughes I; Abdeen MH; Ng JHK
Cochrane Database Syst Rev; 2021 May; 5(5):CD006687. PubMed ID: 33998674
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
Thompson AE; Pope JE
Rheumatology (Oxford); 2005 Feb; 44(2):145-50. PubMed ID: 15546967
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers for inhibiting preterm labour and birth.
Flenady V; Wojcieszek AM; Papatsonis DN; Stock OM; Murray L; Jardine LA; Carbonne B
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD002255. PubMed ID: 24901312
[TBL] [Abstract][Full Text] [Related]
9. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate for psoriatic arthritis.
Wilsdon TD; Whittle SL; Thynne TR; Mangoni AA
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012722. PubMed ID: 30656673
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib for osteoarthritis.
Puljak L; Marin A; Vrdoljak D; Markotic F; Utrobicic A; Tugwell P
Cochrane Database Syst Rev; 2017 May; 5(5):CD009865. PubMed ID: 28530031
[TBL] [Abstract][Full Text] [Related]
12. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
[TBL] [Abstract][Full Text] [Related]
13. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
14. Oral vasodilators for primary Raynaud's phenomenon.
Vinjar B; Stewart M
Cochrane Database Syst Rev; 2008 Apr; (2):CD006687. PubMed ID: 18425964
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.
Khouri C; Lepelley M; Bailly S; Blaise S; Herrick AL; Matucci-Cerinic M; Allanore Y; Trinquart L; Cracowski JL; Roustit M
Lancet Rheumatol; 2019 Dec; 1(4):e237-e246. PubMed ID: 38229380
[TBL] [Abstract][Full Text] [Related]
16. Non-steroidal anti-inflammatory drugs for acute gout.
van Durme CM; Wechalekar MD; Buchbinder R; Schlesinger N; van der Heijde D; Landewé RB
Cochrane Database Syst Rev; 2014 Sep; (9):CD010120. PubMed ID: 25225849
[TBL] [Abstract][Full Text] [Related]
17. Oral vasodilators for primary Raynaud's phenomenon.
Stewart M; Morling JR
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD006687. PubMed ID: 22786498
[TBL] [Abstract][Full Text] [Related]
18. Colchicine for acute gout.
McKenzie BJ; Wechalekar MD; Johnston RV; Schlesinger N; Buchbinder R
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD006190. PubMed ID: 34438469
[TBL] [Abstract][Full Text] [Related]
19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
